GC
CRSP icon

Gould Capital’s CRISPR Therapeutics CRSP Stock Holding History

Gould Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33K Hold
70
– – ﹤0.01% 166
2025
Q4 		$3.67K Hold
70
– – ﹤0.01% 164
2025
Q3 		$4.54K Hold
70
– – ﹤0.01% 163
2025
Q2 		$3.4K Hold
70
– – ﹤0.01% 172
2025
Q1 		$2.38K Hold
70
– – ﹤0.01% 176
2024
Q4 		$2.75K Sell
70
-35
-33% -$1.65K ﹤0.01% 172
2024
Q3 		$4.93K Hold
105
– – ﹤0.01% 167
2024
Q2 		$5.67K Hold
105
– – ﹤0.01% 162
2024
Q1 		$7.16K Hold
105
– – 0.01% 156
2023
Q4 		$6.57K Sell
105
-5
-5% -$276 ﹤0.01% 162
2023
Q3 		$4.67K Hold
110
– – ﹤0.01% 163
2023
Q2 		$6.17K Hold
110
– – ﹤0.01% 160
2023
Q1 		$4.97K Buy
110
+20
+22% +$971 ﹤0.01% 169
2022
Q4 		$3.66K Hold
90
– – ﹤0.01% 176
2022
Q3 		$6K Hold
90
– – 0.01% 155
2022
Q2 		$5K Hold
90
– – ﹤0.01% 163
2022
Q1 		$6K Hold
90
– – ﹤0.01% 159
2021
Q4 		$7K Buy
+90
New +$7.86K ﹤0.01% 168

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gould Capital's CRSP Position: Q1 2026 in Review

Gould Capital held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 70 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #166.

Gould Capital first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $7.16K in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Gould Capital held 70 shares of CRISPR Therapeutics worth $3.33K as of Q1 2026.
  • Gould Capital left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Gould Capital's portfolio in Q1 2026, its #166 holding.
  • Gould Capital first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Gould Capital's CRISPR Therapeutics position peaked at $7.16K in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Gould Capital's 13F filing for Q1 2026, filed 18 May 2026.